TScan Therapeutics, Inc.

The company is a clinical-stage biotechnology company focused on developing T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for cancer patients. Its lead product candidate, TSC-101, is being developed to treat acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in patients undergoing allogeneic hematopoietic cell transplantation (HCT). TSC-101 aims to eliminate residual disease and promote complete donor chimerism to prevent relapse. This product targets HA-2, an antigen found on all blood cells in patients with the HLA type A*02:01. The company is conducting a Phase 1 clinical study for TSC-101 (the ALLOHA™ trial, NCT05473910). In the fourth quarter of 2025, following a meeting with the U.S. Food and Drug Administration (FDA), an agreement was reached on a registrational path for TSC-101 for AML and MDS patients. The pivotal study will be similar to the ongoing Phase 1 ALLOHA study, using a biologically-assigned control arm with relapse-free survival as the primary endpoint. The company is expanding its hematologic (heme) malignancies program with additional TCRs targeting other HLA types. TSC-102-A01 and TSC-102-A03 are allogeneic, donor-derived TCR-T therapy candidates targeting epitopes from CD45. These candidates, like TSC-101, are designed to eliminate residual cancer cells and prevent relapse in HCT patients. TSC-102-A01 is for patients with HLA type A*01:01, and TSC-102-A03 is for those with HLA type A*03:01. The company is also developing multiple TCR-T therapy product candidates for solid tumors. To address tumor heterogeneity, the company is developing multiplex TCR-T therapy, which involves treating a patient with more than one TCR-T therapy product candidate simultaneously. These multiplex therapies are designed for simultaneous administration of up to three highly active TCR-Ts, customized for each patient based on the targets expressed in their tumors.